ArticleClinical rheumatology2021
Characterization of visual manifestations and identification of risk factors for permanent vision loss in patients with giant cell arteritis.
Article in Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05703763 (The Applanation Tonometry in Giant Cell Arteritis Pilot), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Applanation Tonometry in Giant Cell Arteritis Pilot
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Headache as the most common manifestation of giant cell arteritis?: a systematic review with meta-analysis.Rheumatology international · 2025Pooled it
- Diagnostic Challenges and Modern Therapeutic Strategies in Giant Cell Arteritis.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- The Set up and the Triggers: An Update on the Risk Factors for Giant Cell Arteritis.Current neurology and neuroscience reports · 2024Review
- Characteristics associated with anterior ischemic optic neuropathy (AION) in giant cell arteritis (GCA).Clinical rheumatology · 2024Article
- Optic Nerve Sheath Measurement on Ultrasound: A Novel Diagnostic Test for Giant Cell Arteritis.ACR open rheumatology · 2024Article
- Antiplatelet therapy to prevent ischemic events in giant cell arteritis: protocol for a systematic review and meta-analysis.Systematic reviews · 2024Article
- Assessment and comparison of probability scores to predict giant cell arteritis.Clinical rheumatology · 2024Article
- Frequency of visual involvement in a 10-year interdisciplinary cohort of patients with giant cell arteritis.Clinical medicine (London, England) · 2023Article
- Rare Ischemic Complications of Giant Cell Arteritis: Case Series and Literature Review.The American journal of case reports · 2022Review
- Tocilizumab in visual involvement of giant cell arteritis: a multicenter study of 471 patients.Therapeutic advances in musculoskeletal disease · 2022Article
- Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background/purposePermanent vision loss (PVL) is a feared complication and a leading cause of morbidity in giant cell arteritis (GCA). The objective of this study is to describe visual manifestations and identify risk factors of ocular involvement in GCA.
methodsA retrospective database from a single vasculitis referral center was used. Descriptive statistics comparing patients with and without ocular involvement were performed.
resultsOne hundred patients with GCA were included. Visual symptoms were present in 53% of patients at diagnosis and included blurred vision (30%), diplopia (16%), amaurosis fugax (14%), and blindness (19%). Out of 19 patients with blindness, 16 did not recover and had PVL. Patients with PVL were older (79.2 ± 6.7 vs 74.2 ± 7.6 years; p = 0.008) and more likely to have coronary artery disease (31% vs 10%; p = 0.018). However, they were less likely to have other cranial symptoms (81% vs 96%; p = 0.019), mainly headaches (64% vs 92%; p = 0.003). Risk factors associated with an abnormal ophthalmologic examination were the same as for PVL, but patients were also more likely to have diabetes (29% vs 7%; p = 0.040) and less likely to have constitutional symptoms (53% vs 80%; p = 0.033).
conclusionPatients with GCA and ocular involvement were more likely to have baseline diabetes and atherosclerosis. A predisposing vascular vulnerability might therefore increase the risk of ocular involvement. Key points • Most patients with GCA and complete vision loss at presentation will not recover and evolve to have permanent vision loss. • A GCA patient with visual manifestations at presentation has more baseline vascular risk factors (diabetes, atherosclerosis) than patients without ocular involvement. • Patients with GCA and visual manifestations have fewer constitutional symptoms and lower inflammatory markers than patients without ocular involvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.